etomoxir has been researched along with Diabetes Mellitus, Type 2 in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arduini, A; Ceccarelli, SM; Chomienne, O; Gubler, M | 1 |
| He, W; Li, J; Liao, B; Yang, J | 1 |
| Marazzi, G; Rosano, GM; Volterrani, M | 1 |
| Grill, V; Ling, ZC; Ostenson, CG; Zhou, YP | 1 |
| Bristow, M | 1 |
| Gries, FA; Hübinger, A; Weikert, G; Wolf, HP | 1 |
| Fasching, P; Korn, A; Nowotny, P; Ratheiser, K; Rohac, M; Schneeweiss, B; Waldhäusl, W; Wolf, HP | 1 |
1 trial(s) available for etomoxir and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
The effect of etomoxir on insulin sensitivity in type 2 diabetic patients.
Topics: Aged; Diabetes Mellitus, Type 2; Epoxy Compounds; Fatty Acids, Nonesterified; Female; Glucose; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Triglycerides | 1992 |
6 other study(ies) available for etomoxir and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
Topics: Animals; Carnitine; Carnitine O-Palmitoyltransferase; Catalytic Domain; Diabetes Mellitus, Type 2; Energy Metabolism; Enzyme Activators; Ethylene Oxide; Heart Failure; Humans; Insulin Resistance; Isoenzymes; Lipid Metabolism; Myocardial Ischemia; Organ Specificity; Protein Conformation; Sequence Homology, Amino Acid; Stereoisomerism | 2011 |
FFA-ROS-P53-mediated mitochondrial apoptosis contributes to reduction of osteoblastogenesis and bone mass in type 2 diabetes mellitus.
Topics: Adult; Animals; Apoptosis; Benzothiazoles; Bone Density; Cross-Sectional Studies; Diabetes Mellitus, Type 2; DNA, Mitochondrial; Epoxy Compounds; Fatty Acids, Nonesterified; Humans; Lipid Peroxidation; Male; Mice, Inbred C57BL; Middle Aged; Mitochondria; Organophosphorus Compounds; Osteoblasts; Osteogenesis; Reactive Oxygen Species; Toluene; Tumor Suppressor Protein p53; Ubiquinone | 2015 |
Metabolic agents in the management of diabetic coronary patients: a new era.
Topics: Acetanilides; Citric Acid Cycle; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dichloroacetic Acid; Enzyme Inhibitors; Epoxy Compounds; Humans; Insulin Resistance; Perhexiline; Piperazines; Ranolazine; Trimetazidine; Vasodilator Agents | 2008 |
Deficiency of pyruvate dehydrogenase activity in pancreatic islets of diabetic GK rats.
Topics: Acetates; Animals; Diabetes Mellitus, Type 2; Epoxy Compounds; Female; Glucose; Hypoglycemic Agents; In Vitro Techniques; Insulin; Insulin Secretion; Islets of Langerhans; Protein Kinases; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Pyruvate Dehydrogenase Complex; Pyruvate Dehydrogenase Complex Deficiency Disease; Pyruvates; Pyruvic Acid; Rats; Rats, Inbred Strains; Rats, Wistar; Succinates; Succinic Acid | 1995 |
Etomoxir: a new approach to treatment of chronic heart failure.
Topics: Animals; Carnitine O-Palmitoyltransferase; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Epoxy Compounds; Heart Failure; Humans; Hypoglycemic Agents; Rats | 2000 |
Inhibition by etomoxir of carnitine palmitoyltransferase I reduces hepatic glucose production and plasma lipids in non-insulin-dependent diabetes mellitus.
Topics: 3-Hydroxybutyric Acid; Adult; Alanine Transaminase; Carnitine O-Palmitoyltransferase; Cholesterol; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Epoxy Compounds; Fatty Acids, Nonesterified; Glucose; Glucose Clamp Technique; Humans; Hydroxybutyrates; Hypoglycemic Agents; Lactates; Lactic Acid; Lipids; Liver; Middle Aged; Triglycerides | 1991 |